These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6422325)

  • 1. Valproic acid-induced hyperammonemia in mentally retarded adults.
    Williams CA; Tiefenbach S; McReynolds JW
    Neurology; 1984 Apr; 34(4):550-3. PubMed ID: 6422325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproate-induced hyperammonemia.
    Batshaw ML; Brusilow SW
    Ann Neurol; 1982 Mar; 11(3):319-21. PubMed ID: 6807193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman.
    Mallet L; Babin S; Morais JA
    Ann Pharmacother; 2004 Oct; 38(10):1643-7. PubMed ID: 15316109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
    Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymptomatic hyperammonemia in patients receiving valproic acid.
    Murphy JV; Marquardt K
    Arch Neurol; 1982 Sep; 39(9):591-2. PubMed ID: 6810855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.
    Aires CC; van Cruchten A; Ijlst L; de Almeida IT; Duran M; Wanders RJ; Silva MF
    J Hepatol; 2011 Aug; 55(2):426-34. PubMed ID: 21147182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
    Inoue K; Suzuki E; Takahashi T; Yamamoto Y; Yazawa R; Takahashi Y; Imai K; Miyakawa K; Inoue Y; Tsuji D; Hayashi H; Itoh K
    Epilepsy Res; 2014 Aug; 108(6):1046-51. PubMed ID: 24888247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-Arginine in the treatment of valproate overdose - five clinical cases.
    Schrettl V; Felgenhauer N; Rabe C; Fernando M; Eyer F
    Clin Toxicol (Phila); 2017 Apr; 55(4):260-266. PubMed ID: 28152637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cerebral edema with hyperammonemia in valpromide poisoning. Manifestation in an adult, of a partial deficit in type I carbamylphosphate synthetase].
    Bourrier P; Varache N; Alquier P; Rabier D; Kamoun P; Lorre G; Alhayek G
    Presse Med; 1988 Nov; 17(39):2063-6. PubMed ID: 2974563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carnitine deficiency and hyperammonemia associated with valproic acid therapy.
    Ohtani Y; Endo F; Matsuda I
    J Pediatr; 1982 Nov; 101(5):782-5. PubMed ID: 6813444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproate-induced hyperammonemic encephalopathy.
    Segura-Bruna N; Rodriguez-Campello A; Puente V; Roquer J
    Acta Neurol Scand; 2006 Jul; 114(1):1-7. PubMed ID: 16774619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproate use associated with persistent hyperammonemia and mitochondrial injury in a child with Down's syndrome.
    Kane RE; Kotagel S; Bacon BR; Vogler CA
    J Pediatr Gastroenterol Nutr; 1992 Feb; 14(2):223-7. PubMed ID: 1534366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy.
    Matsuda I; Ohtani Y; Ninomiya N
    J Pediatr; 1986 Jul; 109(1):131-4. PubMed ID: 3088240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy.
    Honeycutt D; Callahan K; Rutledge L; Evans B
    Neurology; 1992 Mar; 42(3 Pt 1):666-8. PubMed ID: 1549234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report.
    Cheung E; Wong V; Fung CW
    J Child Neurol; 2005 Feb; 20(2):157-60. PubMed ID: 15794187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymptomatic hyperammonemia in children treated with valproic acid.
    Altunbaşak S; Baytok V; Tasouji M; Hergüner O; Burgut R; Kayrin L
    J Child Neurol; 1997 Oct; 12(7):461-3. PubMed ID: 9373804
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient.
    Kulick SK; Kramer DA
    Ann Emerg Med; 1993 Mar; 22(3):610-2. PubMed ID: 8192712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute hyperammonemic coma with chronic valproic acid therapy.
    Cuturic M; Abramson RK
    Ann Pharmacother; 2005 Dec; 39(12):2119-23. PubMed ID: 16288075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproate-induced Hyperammonemic Encephalopathy Presenting as Catatonia.
    Pérez-Esparza R; Oñate-Cadena N; Ramírez-Bermúdez J; Espínola-Nadurille M
    Neurologist; 2018 Mar; 23(2):51-52. PubMed ID: 29494435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.